Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

Like a lot of people, I’d had some squamous cell carcinomas removed from my scalp. But in June, 2024, a red splotch, about the size of my fist, appeared on ...

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...